SCHEMBL13639753

SCHEMBL13639753

COc1ccc(-c2cccc(C(=O)Nc3cccc(C(F)(F)F)c3)c2)c(OC)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 4/20 0.62
MAPT P10636 4/20 0.60
PLG P00747 1/20 0.60
PLAU P00749 1/20 0.60
PLAT P00750 1/20 0.60
TAS1R3 Q7RTX0 1/20 0.57
TAS1R1 Q7RTX1 1/20 0.57
TAS1R2 Q8TE23 1/20 0.57
POLB P06746 3/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
HTT P42858 2/20 0.55
RAB9A P51151 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.54
GAA P10253 1/20 0.54
MAPK1 P28482 1/20 0.54
KCNK3 O14649 2/20 0.54
KCNK9 Q9NPC2 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4186005 0.84 SMN1; SMN2 (0.71) RXFP1MAPTPLGPLAUPLAT
SCHEMBL4174639 0.84 NPC1 (0.74) RXFP1MAPTPOLBCYP1A2CYP3A4
SCHEMBL12581365 0.82 RXFP1 (0.63) RXFP1MAPTPLGPLAUPLAT
SCHEMBL13561150 0.79 MAPT (0.68) RXFP1MAPTPOLBMEN1KMT2A
SCHEMBL30926407 0.79 MEN1 (0.59) RXFP1MAPTPOLBMEN1KMT2A
SCHEMBL27181159 0.79 MEN1 (0.59) RXFP1MAPTPOLBMEN1KMT2A
SCHEMBL13639740 0.79 MAPT (0.67) RXFP1MAPTPOLBMEN1KMT2A
SCHEMBL15528441 0.78 RXFP1 (0.79) RXFP1MAPTCYP1A2CYP3A4KCNK3
SCHEMBL4286068 0.77 MAPT (0.94) RXFP1MAPTPOLBMEN1KMT2A
SCHEMBL3028309 0.77 MAPT (0.76) RXFP1MAPTPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1948146-B1 NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE REVOTAR BIOPHARMACEUTICALS AG (DE) 2012-11-07 EP disclosed
US-20090030015-A1 NOVEL MULTI-CYCLIC COMPOUNDS REVOTAR BIOPHARMACEUTICALS AG (DE) 2009-01-29 US disclosed
US-20090030015-A1 NOVEL MULTI-CYCLIC COMPOUNDS REVOTAR BIOPHARMACEUTICALS AG (DE) 2009-01-29 US disclosed
WO-2007039111-A2 NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE REVOTAR BIOPHARMACEUTICALS AG (DE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030015-A1 NOVEL MULTI-CYCLIC COMPOUNDS SELP, SELE, SELL RXFP1 2767/4885MAPT 4021/4885PLG 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.